SARS-CoV-2 vaccines reduce the risk of COVID-19. 1–3 However, some disease-modifying
anti-rheumatic drugs (DMARDs), particularly glucocorticoids, methotrexate, mycophenolate …

Objective To describe disease-modifying antirheumatic drug (DMARD) disruption,
rheumatic disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …

Objective Patients with immune‐mediated diseases treated with anti‐CD20 monoclonal
antibodies may have worse coronavirus disease 2019 (COVID‐19) outcomes due to impaired …

Background COVID-19 can induce a hyperinflammatory state, which might lead to poor clinical
outcomes. We aimed to assess whether patients with a systemic rheumatic disease might …

Objective To investigate passive smoking throughout the life course and the risk of rheumatoid
arthritis (RA), while accounting for personal smoking. Methods We analyzed the Nurses’ …

Objective To identify predictors of rheumatic immune‐related adverse events (irAEs) following
immune checkpoint inhibitor (ICI) treatment for cancer. Methods We performed a case–…

Objectives We performed a systematic review and meta-analysis for the prevalence and risk
factors of rheumatoid arthritis-related bronchiectasis (RA-BR). Methods We queried PubMed …

Several inhalants other than personal cigarette smoking may be associated with increased
risk for developing RA. These results support the hypothesis that inhalants, pulmonary …

Objective To investigate the independent relationship of rheumatoid arthritis (RA) to the type
and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in …

Objective COVID‐19 patients with rheumatic disease have a higher risk of mechanical
ventilation than the general population. The present study was undertaken to assess lung …